The Lancet Oncology

The Lancet Oncology is a peer-reviewed medical journal specializing in oncology research, clinical trials, and policy analysis. Launched in 2000, it forms part of the Lancet family of journals and regularly publishes original research, reviews, commentaries, and practice guidelines. The journal interfaces with academic institutions, healthcare organizations, regulatory agencies, and philanthropic funders to shape clinical oncology practice and cancer policy internationally.

History

The journal was established in 2000 amid evolving priorities in cancer research and clinical care associated with institutions such as Royal Marsden Hospital, Institute of Cancer Research, MD Anderson Cancer Center, Dana–Farber Cancer Institute, and Memorial Sloan Kettering Cancer Center. Early editorial initiatives engaged with major trials from cooperative groups including European Organisation for Research and Treatment of Cancer, National Cancer Institute (United States), and Cancer Research UK. Coverage amplified developments tied to pharmaceutical companies like GlaxoSmithKline, AstraZeneca, Pfizer, Roche (Genentech), and Novartis. Landmark reports paralleled global health events involving World Health Organization, Gavi, the Vaccine Alliance, and Bill & Melinda Gates Foundation, while commenting on policy debates in jurisdictions such as United Kingdom, United States, European Union, India, and China. The journal has published influential trials and meta-analyses connected to researchers affiliated with Oxford University, Cambridge University, Harvard University, Johns Hopkins University, and Stanford University and reported on regulatory decisions from agencies like European Medicines Agency and U.S. Food and Drug Administration.

Scope and Content

The journal covers translational oncology, clinical trials, epidemiology, and health services research intersecting with centers such as Memorial Sloan Kettering Cancer Center, Fred Hutchinson Cancer Center, Sloan Kettering Institute, and Karolinska Institutet. Topics routinely include targeted therapies related to genes and pathways studied at Broad Institute, Wellcome Sanger Institute, Cancer Genome Atlas, and European Molecular Biology Laboratory; immuno-oncology advances linked to James P. Allison, Tasuku Honjo, Dana–Farber Cancer Institute, and Parker Institute for Cancer Immunotherapy; and radiotherapy innovations associated with Cleveland Clinic, Mayo Clinic, and Paul Scherrer Institute. The journal publishes guidelines and consensus statements involving societies like American Society of Clinical Oncology, European Society for Medical Oncology, Royal College of Radiologists, and International Agency for Research on Cancer. Reviews engage with major works and trials conducted by networks such as Cooperative Oncology Group, EORTC, The Cancer Genome Atlas Research Network, International Cancer Genome Consortium, and funders such as Wellcome Trust and Howard Hughes Medical Institute.

Editorial Leadership and Peer Review

Editorial leadership has included editors and advisory board members drawn from universities and hospitals such as University of Oxford, University of Cambridge, Imperial College London, University College London, Yale University, Columbia University, University of Melbourne, and University of Tokyo. Peer review practices align with standards promoted by organizations like Committee on Publication Ethics, International Committee of Medical Journal Editors, World Association of Medical Editors, and CrossRef. The journal handles submissions from principal investigators at sites including Dana–Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and Vanderbilt University Medical Center and coordinates statistical review drawing on expertise from groups such as Statistical Society of Australia and university departments at University of California, Berkeley and University of Chicago. Editorial decisions have intersected with debates around conflicts of interest involving pharmaceutical sponsors such as Bristol Myers Squibb and Merck & Co..

Publication and Access Model

Published by Elsevier (publisher) as part of the Lancet group, the journal operates within subscription and open-access frameworks similar to titles such as The Lancet, Lancet Oncology Weekly (if applicable), and specialty journals like Nature Medicine and Journal of Clinical Oncology. The journal’s policies reflect licensing practices common to publishers including Springer Nature, Wiley-Blackwell, and Oxford University Press and respond to mandates from funders such as Wellcome Trust, National Institutes of Health, European Research Council, and UK Research and Innovation. Indexing occurs in databases maintained by organizations such as PubMed Central, Web of Science, Scopus, and CrossRef, and the journal’s articles inform clinical guidelines issued by bodies like National Institute for Health and Care Excellence and American Cancer Society.

Impact and Reception

The journal has influenced clinical practice and research priorities through publications cited by guideline-producing organizations including National Comprehensive Cancer Network, American Society of Clinical Oncology, European Society for Medical Oncology, and International Agency for Research on Cancer. High-impact trials and commentaries published have been discussed in major media outlets and policy forums involving United Nations, World Health Organization, G20, and national health ministries in United Kingdom, United States, India, and China. Citation metrics align it with leading oncology journals such as Journal of Clinical Oncology, Cancer Cell, Nature Reviews Cancer, The New England Journal of Medicine, and Lancet Respiratory Medicine in shaping research agendas. The journal’s reporting has at times prompted responses from regulatory agencies like European Medicines Agency and U.S. Food and Drug Administration and informed debates among professional societies including American Association for Cancer Research and Society for Immunotherapy of Cancer.

Category:Medical journals